BAOZUN-W (09991) released its annual performance with a net loss of 242 million yuan, a year-on-year increase of 30.72%.
Paozun E-commerce-W (09991) announced its performance for the fourth quarter of 2025 and the fiscal year 2025. In the fourth quarter of 2025, the group achieved a total net revenue of 3.172 billion yuan, a year-on-year increase of 5.9%; the net loss attributable to ordinary shareholders was 37.957 million yuan, which changed from profit to loss compared to the same period last year.
BAOZUN-W (09991) released its performance for the fourth quarter of 2025 and the fiscal year 2025. In the fourth quarter of 2025, the Group achieved a total revenue of 3.172 billion yuan, an increase of 5.9% year-on-year; the net loss attributable to ordinary shareholders was 37.957 million yuan, a turnaround from profit to loss year-on-year.
In the fiscal year 2025, the Group achieved a total revenue of 9.946 billion yuan, an increase of 5.6% year-on-year; the net loss attributable to ordinary shareholders was 242 million yuan, an increase of 30.72% year-on-year; basic loss per share was 1.40 yuan; operating profit was 56.555 million yuan.
The announcement stated that product sales revenue in 2025 was 3.85 billion yuan, an increase of 11.0% from the fiscal year 2024 revenue of 3.467 billion yuan, including: product sales revenue from e-commerce business was 2.01 billion yuan, compared to about 2 billion yuan in fiscal year 2024.
Related Articles

CT VISION (00994) issues profit warning, expecting shareholders' share of net loss for the year 2025 to be not less than HK$33 million.

WEILI HOLDINGS (02372) releases annual performance, with a net loss attributable to shareholders of 4.1 million yuan, a year-on-year decrease of 56.8%.

From turning point of profit to platform going overseas, the 2025 report reveals the advanced path of Lepubio Biopharma (02157).
CT VISION (00994) issues profit warning, expecting shareholders' share of net loss for the year 2025 to be not less than HK$33 million.

WEILI HOLDINGS (02372) releases annual performance, with a net loss attributable to shareholders of 4.1 million yuan, a year-on-year decrease of 56.8%.

From turning point of profit to platform going overseas, the 2025 report reveals the advanced path of Lepubio Biopharma (02157).






